- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04027894
Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years
Double Blind Study to Evaluate the Safety and Efficacy of 400 mg Twice Daily Rifamycin SV MMX® Added to Standard Oral Rehydration Therapy (ORT) Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 12 to 17 Years
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Approximately 142 subjects are expected to be enrolled in the study, 1:1 in the Rifamycin SV MultiMatrix (MMX) plus Oral RehydrationTherapy (ORT) group and in the placebo tablets plus ORT group respectively. The day of randomization (Visit 1, Day 1), the subjects will start the treatment receiving ORT plus Rifamycin SV MMX 400 mg (as two tablets of 200 mg each) twice daily (morning and evening) or ORT plus placebo tablets (as two tablets) twice daily (morning and evening). The subjects will begin the treatment within 72 hours of onset of diarrhea. Treatment duration will last 72 hours. The total number of tablets for the entire treatment course will be 12 (4 × 200 mg tablets/day for 3 days). The administration of the ORT will follow the specification reported in the product label. The tablets will be orally administered during the day. No tablet administration will be done during the night.
After enrollment, subjects/their parents/or guardians will complete Diary Cards (PDC) in which will be daily recorded date, time of first tablets intake, time and consistency of each stool, presence of blood in stools, abdominal pain/cramps, flatulence, tenesmus, urgency, nausea, vomiting, fever, adverse events (AEs), and concomitant medications.
During the study, the subjects will be assessed for safety and efficacy at Visit 2 (Day 2) and Visit 3 (Day 4/5) as final Study Visit.
Stool samples for microbiological assessment will be collected at Visits 1 and 3. Stool will be examined and cultured at local labs for main enteropathogens and for the presence of protozoa, ova and yeasts.
Stool samples will be required in a subset population of the Rifamycin SV MMX group, at the Follow-up visit to determine rifamycin concentration in the feces.
Blood and urine sampling for routine safety analyses will be collected at Visit 1 and at Visit 3.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Gilead Raday, M.Sc.
- Phone Number: +972-3-6398893
- Email: gilead@redhillbio.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of acute bacterial diarrhea defined as at least 3 unformed stools within the 24 hours preceding randomization, with a duration of illness ≤72 h. The bacterial origin of diarrhea will be confirmed "a posteriori" by stool microbiology sampling at the time of screening.
- Presence of one or more signs or symptoms of enteric infection have to be present, including nausea, vomiting, abdominal cramps or pain, tenesmus, urgency
- History of recent travel from an industrialized country to a developing region with a known high incidence of travelers' diarrhea
- Male or female 12-17 years of age, providing an unformed pre-treatment stool
- Females of child-bearing potential must use an acceptable contraceptive method throughout the study treatment period
- The parent or legally acceptable representative guardian must provide informed consent for the subject. The Subject must also provide written informed assent by the parent or legal guardian at the time of assent/consent signing.
Exclusion Criteria:
- Fever (>100.4ºF or 38ºC), or presence of signs and symptoms of systemic infection
- Females pregnant or breast feeding or not using adequate birth control
- Known or suspected infection with non-bacterial pathogen
- Symptoms of acute diarrhea of >72 hours duration
- Presence of grossly bloody stool
- Moderate to severe dehydration
- History of inflammatory bowel disease (IBD)
- Abdominal ileus
- Severe dehydration
- Greater than two doses of an antidiarrheal medication within 24 hours before randomization, or any symptomatic therapy within 2 hours before enrolment
- Receiving antimicrobial drug with expected activity against enteric bacterial pathogens within the week prior to enrolment
- Hypersensitivity to rifamycin-related antibiotics or to any excipient included in the study medications
- Subjects unable/unwilling to comply with study protocol
- Participation in a clinical trial within the last 30 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rifamycin SV MMX plus ORT
Each tablet contains 200mg Rifamycin SV MMX for oral administration
|
200 mg Rifamycin SV-MMX® (CB-01-11)
Other Names:
|
Placebo Comparator: Placebo tablets plus ORT
Placebo tablets identical to Rifamycin tablets with respect to size, taste and appearance.
|
Placebo to Rifamycin SV-MMX® Placebo tablets correspond to active tablets with respect to size, taste, and appearance.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Cure
Time Frame: 120 hours
|
Passage of two or fewer soft stools and no watery stools, no fever (> 100.4 ºF or 38 ºC), and no signs or symptoms of enteric infection (other than mild excess gas/flatulence) during a 24-hour interval in the 120-hour data collection period after the first dose of study drug or Passage of no stools or only formed stools and no fever during a 48-hour interval in the 120-hour data collection period after the first dose of study drug, with or without other signs or symptoms of enteric infection.
|
120 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Last Unformed Stool (TLUS)
Time Frame: 120 hours
|
defined as the interval in hours between the first dose of study drug and the last unformed stool passed, after which clinical cure was declared.
Subjects who meet the criteria for clinical cure immediately after the start of the study and prior to passing any unformed stools are defined as having a TLUS of 0 hours.
Subject who terminated the study early due treatment failure will have a censored TLUS set to 120 hours.
|
120 hours
|
Microbiological Cure
Time Frame: 120 hours
|
the proportion of subjects with an identified pathogen at baseline with microbiological eradication in the post-treatment stool sample.
|
120 hours
|
Treatment Failure
Time Frame: 120 hours
|
Defined as either of the following: Worsening diarrhea and/or signs or symptoms of enteric infection or failure to improve 24 hours or more after the first dose of study drug that results in administration of rescue therapy and/or Not achieving Clinical Cure in the 120-hr data collection period after the first dose of study drug or use of antimicrobial prohibited concomitant medication.
|
120 hours
|
Improvement
Time Frame: 24 hours
|
Defined as ≥ 50% reduction in the number of unformed stools passing during a 24 h period, in comparison with the number of stools passed during the 24 h immediately before enrolment in the study.
|
24 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: June Almenoff, MD, PhD, RedHill Biopharma, Inc.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CB-01-11/30
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Traveler's Diarrhea
-
Intercell USA, Inc.CompletedTraveler's DiarrheaUnited States
-
Cosmo Technologies LtdBausch Health Americas, Inc.CompletedTraveler's DiarrheaGuatemala, Mexico
-
NIZO Food ResearchPanTheryx, Inc.CompletedTraveler's DiarrheaNetherlands
-
RedHill Biopharma LimitedNot yet recruiting
-
Clasado Biosciences LtdWithdrawnTraveler's Diarrhea
-
Intercell USA, Inc.CompletedTraveler's DiarrheaIndia, United Kingdom, Germany
-
Dr. Falk Pharma GmbHCompletedTraveler's DiarrheaEcuador, Guatemala, India
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Lund UniversityCompletedTraveler's Diarrhea | Antibiotic Resistant Infection | Antibiotic Resistant StrainSweden
-
Aboca Spa Societa' AgricolaUnknownDiarrhea | Diarrhea, Infantile | Chronic Diarrhea | Acute Diarrhea
Clinical Trials on Rifamycin SV MMX
-
Dr. Falk Pharma GmbHCompletedUncomplicated DiverticulitisGermany
-
RedHill Biopharma LimitedNot yet recruiting
-
Bradley ConnorEnrolling by invitationGastrointestinal Disease | Small Intestinal Bacterial Overgrowth | Gastrointestinal InfectionUnited States
-
Cosmo Technologies LtdBausch Health Americas, Inc.CompletedTraveler's DiarrheaGuatemala, Mexico
-
Cosmo Technologies LtdCompleted
-
Hunter Holmes Mcguire Veteran Affairs Medical CenterCompletedHepatic Encephalopathy | Cirrhosis, LiverUnited States
-
Cosmo Technologies LtdCompletedInfectious Diarrhoea
-
Cosmo Technologies LtdCompletedDiarrhea-predominant Irritable Bowel SyndromeBelgium, Germany, Italy, Spain
-
National Taiwan University HospitalRecruiting
-
Dr. Falk Pharma GmbHCompletedTraveler's DiarrheaEcuador, Guatemala, India